Cargando…
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells
Targeting anti-apoptotic proteins can sensitize tumor cells to conventional chemotherapies or other targeted agents. Antagonizing the Inhibitor of Apoptosis Proteins (IAPs) with mimetics of the pro-apoptotic protein SMAC is one such approach. We used sensitization compound screening to uncover possi...
Autores principales: | Langdon, Casey G., Wiedemann, Norbert, Held, Matthew A., Mamillapalli, Ramanaiah, Iyidogan, Pinar, Theodosakis, Nicholas, Platt, James T., Levy, Frederic, Vuagniaux, Gregoire, Wang, Shaomeng, Bosenberg, Marcus W., Stern, David F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741938/ https://www.ncbi.nlm.nih.gov/pubmed/26485762 |
Ejemplares similares
-
The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate
por: Bobardt, Michael, et al.
Publicado: (2019) -
DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death
por: Thibault, Benoît, et al.
Publicado: (2018) -
The inhibitor of apoptosis proteins antagonist Debio 1143 promotes the PD-1 blockade-mediated HIV load reduction in blood and tissues of humanized mice
por: Bobardt, Michael, et al.
Publicado: (2020) -
Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model
por: Bellaye, Pierre-Simon, et al.
Publicado: (2018) -
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study
por: Hurwitz, Herbert I., et al.
Publicado: (2015)